Dr. Jyoti Malhotra, MD
Claim this profileRutgers Cancer Institute of New Jersey
Area of expertise
Lung Cancer
Jyoti Malhotra, MD has run 7 trials for Lung Cancer. Some of their research focus areas include:
Cancer
Jyoti Malhotra, MD has run 4 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Rutgers Cancer Institute Of New Jersey
City Of Hope At Irvine Lennar
Clinical Trials Jyoti Malhotra, MD is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Carfilzomib + Sotorasib
for Lung Cancer
This phase I trial tests the safety, side effects, and best dose of carfilzomib in combination with sotorasib in treating patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Carfilzomib is a drug that binds to and inhibits the activity of the protein complex that is responsible for degrading other damaged or unneeded proteins. The inhibition of this protein by carfilzomib can then cause tumor growth inhibition and cell death. Sotorasib is a drug that binds to and inhibits the activity of the KRAS G12C mutant. This may inhibit growth in KRAS G12C-expressing tumor cells. Combining carfilzomib and sotorasib may be a safe and effective treatment option for patients with KRAS G12C-mutated advanced or metastatic NSCLC.
Recruiting
1 award
Phase 1
More about Jyoti Malhotra, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Jyoti Malhotra, MD has experience with
- Atezolizumab
- Nivolumab
- Ipilimumab
- Cisplatin
- Paclitaxel
- Radium-223 Dichloride
Breakdown of trials Jyoti Malhotra, MD has run
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jyoti Malhotra, MD specialize in?
Jyoti Malhotra, MD focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jyoti Malhotra, MD currently recruiting for clinical trials?
Yes, Jyoti Malhotra, MD is currently recruiting for 6 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Jyoti Malhotra, MD has studied deeply?
Yes, Jyoti Malhotra, MD has studied treatments such as Atezolizumab, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Jyoti Malhotra, MD?
Apply for one of the trials that Jyoti Malhotra, MD is conducting.
What is the office address of Jyoti Malhotra, MD?
The office of Jyoti Malhotra, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.